Skip to main content
. 2017 Oct 21;39(6):477–485. doi: 10.1093/eurheartj/ehx584

Table 3.

C-indices for cardiovascular mortality according to the ABC-death score (including alternative biomarkers) compared with the CHA2DS2-VASc in the full cohorts and in subgroups

Full cohort No prior stroke/TIA No prior HF TTR < 65% NOACa
Derivation cohort, Events/N 532/14 611 406/11 858 268/10 080 373/8346 506/7319
 ABC-death (cTnT) 0.76 (0.74, 0.78) 0.76 (0.73, 0.78) 0.74 (0.71, 0.77) 0.77 (0.74, 0.81) 0.74 (0.71, 0.78)
 ABC-death (cTnI) 0.74 (0.73, 0.76) 0.76 (0.74, 0.79) 0.75 (0.72, 0.78) 0.77 (0.74, 0.81) 0.75 (0.72, 0.78)
 All clinical information 0.70 (0.68, 0.73) 0.70 (0.67, 0.72) 0.67 (0.64, 0.71) 0.72 (0.68, 0.75) 0.69 (0.65, 0.72)
 CHA2DS2-VASc 0.58 (0.56, 0.61) 0.56 (0.53, 0.59) 0.59 (0.55, 0.62) 0.56 (0.52, 0.60) 0.58 (0.54, 0.62)
Validation cohort; Events/N 385/8548 306/6893 182/6095 76/1119 391/5697
 ABC-death (cTnT) 0.77 (0.74, 0.79) 0.76 (0.74, 0.79) 0.72 (0.68, 0.75) 0.77 (0.72, 0.82) 0.77 (0.74, 0.80)
 ABC-death (cTnI) 0.75 (0.73, 0.78) 0.75 (0.72, 0.78) 0.70 (0.66, 0.74) 0.74 (0.68, 0.79) 0.76 (0.73, 0.79)
 All clinical information 0.68 (0.66, 0.71) 0.68 (0.65, 0.71) 0.62 (0.58, 0.66) 0.63 (0.57, 0.69) 0.70 (0.67, 0.73)
 CHA2DS2-VASc 0.59 (0.56, 0.62) 0.59 (0.56, 0.62) 0.57 (0.53, 0.61) 0.53 (0.46, 0.59) 0.61 (0.57, 0.64)

All clinical information—a model solely consisting of clinical variables (age, gender, smoking, alcohol, prior stroke/TIA, diabetes, hypertension, heart failure, prior myocardial infarction, peripheral arterial disease, vascular disease, AF-type, and prior bleeding).

CHA2DS2-VASc—assigns 1 point each for Congestive heart failure, Hypertension, Diabetes mellitus, Vascular disease, Age 65–74 years, and Gender category (female gender), and 2 points for Age ≥ 75 years and, prior Stroke/transient ischaemic attack).

TTR, time in therapeutic range (INR 2.0–3.0); ABC-death, Age, Biomarkers (cardiac troponin, NT-proBNP, and GDF-15), Clinical history of heart failure); NOAC, non-vitamin K antagonist oral anticoagulation.

a

Apixaban in the derivation cohort and dabigatran in the validation cohort.